UCL School of Pharmacy, University College London , 29/39 Brunswick Square, London WC1N 1AX, U.K.
Nuffield Department of Clinical Medicine, Structural Genomics Consortium, University of Oxford , Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, U.K.
J Med Chem. 2017 Jan 26;60(2):668-680. doi: 10.1021/acs.jmedchem.6b01583. Epub 2017 Jan 9.
The BRPF (bromodomain and PHD finger-containing) family are scaffolding proteins important for the recruitment of histone acetyltransferases of the MYST family to chromatin. Evaluation of the BRPF family as a potential drug target is at an early stage although there is an emerging understanding of a role in acute myeloid leukemia (AML). We report the optimization of fragment hit 5b to 13-d as a biased, potent inhibitor of the BRD of the BRPFs with excellent selectivity over nonclass IV BRD proteins. Evaluation of 13-d in a panel of cancer cell lines showed a selective inhibition of proliferation of a subset of AML lines. Pharmacokinetic studies established that 13-d had properties compatible with oral dosing in mouse models of disease (F 49%). We propose that NI-42 (13-d) is a new chemical probe for the BRPFs suitable for cellular and in vivo studies to explore the fundamental biology of these proteins.
BRPF(溴结构域和 PHD 指含有)家族是一种支架蛋白,对于将 MYST 家族的组蛋白乙酰转移酶招募到染色质中非常重要。尽管在急性髓细胞白血病(AML)中BRPF 家族的作用逐渐被人们所了解,但将其作为潜在的药物靶点进行评估仍处于早期阶段。我们报告了片段 5b 到 13-d 的优化,作为 BRPFs 的 BRD 的偏倚性、强效抑制剂,对非 IV 类 BRD 蛋白具有极好的选择性。在一系列癌细胞系中的评估表明,一组 AML 系的增殖选择性受到抑制。药代动力学研究表明,13-d 具有在疾病小鼠模型中口服给药的特性(F49%)。我们提出,NI-42(13-d)是 BRPFs 的新型化学探针,适用于细胞和体内研究,以探索这些蛋白质的基本生物学。